Pivotal bioVenture Partners
Karoly Nikolich, PhD, joined Pivotal in 2017 and brings a long and successful track record in biotech entrepreneurship and drug discovery. He led Genentech’s entry into neuroscience during the 1980s and led and participated in the development of numerous protein therapeutics. He was Vice President of Research and Development at Lynx Therapeutics, a company that pioneered massively parallel nucleotide sequencing. He also served as Executive Director of the Stanford Neuroscience Institute in 2005-2007.
Karoly was also co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, including Neuropore, Angiochem, Hummingbird, Pascal, as well as several investment funds.
Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Adjunct Professor in the Department of Psychiatry at Stanford University Medical School.
This person is not in any offices
Pivotal bioVenture Partners
Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to serve the growing unmet medical needs in Greater China region by building new ventures. Its investment areas include therapeutics, medical devices, and medical services. The Pivotal China team includes experienced life science investors and entrepreneurs with successful track records of venture building and investing.